CN Patent

CN101454018A — 用于治疗肾病症的方法

Assigned to Genentech Inc · Expires 2009-06-10 · 17y expired

What this patent protects

提供了治疗受试者中的肾病症的方法，其通过对受试者施用有效量的VEGFR激动剂，例如Flt1激动剂。所述激动剂由在制药学可接受载体中包含用于活化Flt1的VEGFR激动剂，例如VEGF、针对Flt1的抗体、Flt1配体、Flt1小分子活化剂、或Flt1选择剂的组合物构成。

USPTO Abstract

提供了治疗受试者中的肾病症的方法，其通过对受试者施用有效量的VEGFR激动剂，例如Flt1激动剂。所述激动剂由在制药学可接受载体中包含用于活化Flt1的VEGFR激动剂，例如VEGF、针对Flt1的抗体、Flt1配体、Flt1小分子活化剂、或Flt1选择剂的组合物构成。

Drugs covered by this patent

atrasentan-hydrochloride (ATRASENTAN HYDROCHLORIDE)

Patent Metadata

Patent number: CN101454018A
Jurisdiction: CN
Classification: —
Expires: 2009-06-10
Drug substance claim: No
Drug product claim: No
Assignee: Genentech Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.